Innovative Digital Platform Ametris offers an advanced end-to-end digital health platform that integrates wearable technologies, regulatory-aligned analytics, and scientific consultation, making it highly attractive for biopharmaceutical companies seeking comprehensive clinical trial solutions.

Strong Industry Presence Participation in major events like the J.P. Morgan Healthcare Conference and recent launches such as DECODE: Obesity demonstrate Ametris' active engagement with leading healthcare stakeholders and its focus on high-impact areas like obesity and real-world evidence.

Expanding Clinical Offerings The launch of digital endpoint collaboration and specialized tools like ActiLife 7 highlights ongoing product innovation and expansion, which can appeal to organizations seeking tailored digital health solutions for complex clinical endpoints.

Significant Market Opportunity With a revenue range of $25M to $50M and collaborations involving major pharmaceutical companies like Eli Lilly, Roche, and Novo Nordisk, Ametris is positioned to grow within the expanding digital health and real-world evidence markets.

Potential Partnership Avenues Ametris’ expertise in transforming real-world patient data into clinical evidence presents multiple partnership opportunities with biotech and pharma companies looking to enhance trial efficiency, meet regulatory standards, and develop digital therapeutics.